New cholesterol drug inclisiran tested in everyday patients

NCT ID NCT05399992

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 847 adults with high cholesterol or mixed dyslipidemia who are starting inclisiran, a newer cholesterol-lowering drug. Researchers want to see how much LDL cholesterol drops after 10 months and how well patients stick with the treatment in real-world settings. The goal is to understand if inclisiran works effectively outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inclisiran
What this could lead to: If successful, this study could show that inclisiran effectively lowers LDL cholesterol in routine care, helping doctors manage high cholesterol more conveniently.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only looks at short-term adherence and cholesterol changes, not long-term health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia, familial combined, LPL related

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIXED DYSLIPIDEMIA PRIMARY HYPERCHOLESTEROLEMIA

Contacts and locations

Locations

Novartis Investigative Site

Feldkirch, 6807, Austria
Novartis Investigative Site

Graz, 8036, Austria
Novartis Investigative Site

Linz, 4021, Austria
Novartis Investigative Site

Sankt Veit im Pongau, 5621, Austria
Novartis Investigative Site

Vienna, 1090, Austria
Novartis Investigative Site

Vienna, 1180, Austria
Novartis Investigative Site

Shenzhen, Guangdong, 518000, China
Novartis Investigative Site

Holon, Gush Dan, 5845997, Israel
Novartis Investigative Site

Petah Tikva, 4941492, Israel
Novartis Investigative Site

Tel Aviv, 6801296, Israel
Novartis Investigative Site

Kuala Lumpur, Kuala Lumpur, 50470, Malaysia
Novartis Investigative Site

Kuala Lumpur, 50400, Malaysia
Novartis Investigative Site

Riyadh, Saudi, 11643, Saudi Arabia
Novartis Investigative Site

Jeddah, 23311, Saudi Arabia
Novartis Investigative Site

Tabuk, 47512, Saudi Arabia
Novartis Investigative Site

Fribourg, CH, 1708, Switzerland
Novartis Investigative Site

Basel, 4031, Switzerland
Novartis Investigative Site

Geneva, 1211, Switzerland
Novartis Investigative Site

Lausanne, 1011, Switzerland
Novartis Investigative Site

Olten, 4600, Switzerland
Novartis Investigative Site

Sankt Gallen, 9007, Switzerland
Novartis Investigative Site

Zurich, 8032, Switzerland
Novartis Investigative Site

Zurich, 8091, Switzerland
Novartis Investigative Site

Abu Dhabi, Abu Dhabi Emirate, 00000, United Arab Emirates
Novartis Investigative Site

Dubai, United Arab Emirates, 7272, United Arab Emirates
Novartis Investigative Site

Abu Dhabi, United Arab Emirates
Novartis Investigative Site

Al Ain City, United Arab Emirates
Novartis Investigative Site

Dubai, United Arab Emirates
Novartis Investigative Site

High Wycombe, Buckinghamshire, HP11 2TR, United Kingdom
Novartis Investigative Site

Louth, Lincolnshire, LN11 7QU, United Kingdom
Novartis Investigative Site

Sunderland, Tyne and Wear, SR4 7TP, United Kingdom
Novartis Investigative Site

Belfast, BT16 1RH, United Kingdom
Novartis Investigative Site

Bromwich, B71 4HJ, United Kingdom
Novartis Investigative Site

Burton-on-Trent, DE13 0RB, United Kingdom
Novartis Investigative Site

Cardiff, CF14 4XW, United Kingdom
Novartis Investigative Site

Hull, HU3 2RW, United Kingdom
Novartis Investigative Site

Lancaster, LA1 4RP, United Kingdom
Novartis Investigative Site

Liverpool, L7 8XP, United Kingdom
Novartis Investigative Site

London, NW3 2QG, United Kingdom
Novartis Investigative Site

Middlesex, UB9 6JH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.